HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AHPA Members Report Problems In Raw Material, Other Supplies In Pandemic Survey For USDA

Executive Summary

Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.

You may also be interested in...



Like COVID-19 Impact On Supply Chain, Expert Says Global Demand For Goods ‘Unprecedented’

UCLA professor Chris Tang says like most US businesses relying on supplies or production from outside the country, particularly from China, consumer health and beauty and personal care product companies should expect at least another year of supply disruption.

DuPont's VMS Industry Customers Increased Launches Despite 2020 Supply Disruptions

Even though three-quarters of DuPont Nutrition & Biosciences’ supplement manufacturing customers experienced supply chain disruptions in 2020, nearly 70% of around 300 surveyed said product development pipeline remains robust. 

US FDA’s ‘Narrow Path’ Squeezes Some Firms New To Sanitizer Space Under Enforcement Discretion

Among firms entering the sanitizer space during COVID-19 pandemic, those adhering to FDA’s GMPs could remain in the market expected to reach $3.65 by 2025. Shook, Hardy and Bacon attorneys say companies should determine whether they realistically can follow FDA’s “narrow path” of regulation.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS149873

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel